search
Back to results

Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer (ASPECT)

Primary Purpose

Lung Cancer, Radiation-Induced Disorder, Radiation Pneumonitis

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Single-photon-emission CT scan
Sponsored by
University of Aarhus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lung Cancer focused on measuring radiation-induced lung toxicity, functional avoidance methodology, radiation therapy of lung cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • histologically verified lung cancer (small-cell and non-small cell lung cancer)
  • referred for radiotherapy with curative intent
  • radiation dose of 60-66 Gy given in 2-Gy fractions, other dose levels and fractionation schedules accepted, as per site standard
  • concurrent chemotherapy is accepted
  • patients with oligometastatic disease are allowed, where metastasis have been ablated with surgery or radiotherapy
  • receiving (chemo)-radiotherapy to the thoracic disease with curative intent
  • adults over 18, that have given oral and written informed consent before patient registration.

Exclusion Criteria:

  • concurrent immunotherapy
  • previous radiotherapy to the thorax
  • other uncontrolled malignancies; any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol

Sites / Locations

  • Sydney West Radiation Oncology Network Westmead and Blacktown Hospitals
  • Department of Oncology, Aarhus University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

SPECT functional avoidance treatment

Standard treatment

Arm Description

SPECT-based radiation therapy given taken functional distribution in the lung into account, that avoids highly functional lung volumes sparing them from radiation.

CT-based radiation therapy given over 5- 6.5 weeks.

Outcomes

Primary Outcome Measures

Radiation-induced lung toxicity
crude rate of symptomatic radiation-induced lung toxicity of grade 2 and higher. According to the Common Toxicity Criteria for Adverse Events version 5.0 for radiation pneumonitis, dyspnea, cough, or any other radiation-induced respiratory, thoracic and mediastinal disorder.

Secondary Outcome Measures

Quality of life
Change in quality of life according to the European Organisation for Research and Treatment of Cancer quality of life questionnaires
Patient reported lung symptoms
Change in lung symptoms according to the European Organisation for Research and Treatment of Cancer questionnaire
Progression-free survival
time from randomization to disease progression at any site or death
Overall survival
time from randomization to death of any cause or last date known alive
Loco-regional control rate
freedom from local disease progression

Full Information

First Posted
December 15, 2020
Last Updated
May 18, 2022
Sponsor
University of Aarhus
Collaborators
Westmead and Blacktown Hospital, Sydney West Radiation Oncology Network, Sydney, Australia, Aarhus University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04676828
Brief Title
Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer
Acronym
ASPECT
Official Title
Functional Lung Avoidance SPECT-guided (ASPECT) Radiation Therapy for Lung Cancer Patients: Phase II Randomised Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2020 (Actual)
Primary Completion Date
December 1, 2023 (Anticipated)
Study Completion Date
December 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Aarhus
Collaborators
Westmead and Blacktown Hospital, Sydney West Radiation Oncology Network, Sydney, Australia, Aarhus University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Study aims to determine if functional lung avoidance based on perfusion single photon emission (SPECT)/CT scan, improves toxicity outcomes for patients with advanced lung cancer undergoing chemo-radiotherapy. Functional avoidance implies a dose plan that takes functional distribution in the lung into account, and avoids highly functional lung volumes sparing them from radiation.
Detailed Description
In this project, a novel method of safe radiotherapy delivery shall be tested for patients with lung cancer in a clinical setting. Functional avoidance radiotherapy is a new method that protect highly functional lung tissue from radiation, while delivering high dose radiotherapy to the lung tumour. Radiotherapy is usually based on a CT scan that does not account for functional variations in the lungs. Therefore, I hypothesize that using functional distribution in the lungs and avoiding irradiation of highly functional lung will improve treatment outcome for individual patients with lung cancer. The objective of my project is to determine if functional image guided radiotherapy (functional avoidance radiotherapy) improves toxicity outcomes for patients with lung cancer undergoing curative chemo-radiotherapy in a prospective clinical trial. To reach this objective, the impact of functional avoidance radiotherapy on pulmonary toxicity measured by the incidence and severity of radiation-induced lung disease shall be assessed. Additionally, loco-regional control, time to progression, overall survival, quality of life and radiation-induced molecular response in patients treated with functional avoidance radiotherapy shall be assessed and compared to patients receiving standard treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Cancer, Radiation-Induced Disorder, Radiation Pneumonitis, Pulmonary Disease, Lung Function Decreased
Keywords
radiation-induced lung toxicity, functional avoidance methodology, radiation therapy of lung cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized double-blinded phase 2
Masking
ParticipantCare ProviderOutcomes Assessor
Masking Description
Participants, care providers and outcome assessors are blinded
Allocation
Randomized
Enrollment
195 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
SPECT functional avoidance treatment
Arm Type
Experimental
Arm Description
SPECT-based radiation therapy given taken functional distribution in the lung into account, that avoids highly functional lung volumes sparing them from radiation.
Arm Title
Standard treatment
Arm Type
No Intervention
Arm Description
CT-based radiation therapy given over 5- 6.5 weeks.
Intervention Type
Diagnostic Test
Intervention Name(s)
Single-photon-emission CT scan
Intervention Description
SPECT/CT scan is an established functional modality used in the diagnosis and monitoring of lung disease. SPECT/CT scan images pulmonary circulation, where perfused areas equate with normal functional lung
Primary Outcome Measure Information:
Title
Radiation-induced lung toxicity
Description
crude rate of symptomatic radiation-induced lung toxicity of grade 2 and higher. According to the Common Toxicity Criteria for Adverse Events version 5.0 for radiation pneumonitis, dyspnea, cough, or any other radiation-induced respiratory, thoracic and mediastinal disorder.
Time Frame
Measured serially from 1 to 12 months after treatment completion
Secondary Outcome Measure Information:
Title
Quality of life
Description
Change in quality of life according to the European Organisation for Research and Treatment of Cancer quality of life questionnaires
Time Frame
Measured serially from 1 to 12 months after treatment completion
Title
Patient reported lung symptoms
Description
Change in lung symptoms according to the European Organisation for Research and Treatment of Cancer questionnaire
Time Frame
Measured serially from 1 to 12 months after treatment completion
Title
Progression-free survival
Description
time from randomization to disease progression at any site or death
Time Frame
at 12 months
Title
Overall survival
Description
time from randomization to death of any cause or last date known alive
Time Frame
at 12 months
Title
Loco-regional control rate
Description
freedom from local disease progression
Time Frame
at 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: histologically verified lung cancer (small-cell and non-small cell lung cancer) referred for radiotherapy with curative intent radiation dose of 60-66 Gy given in 2-Gy fractions, other dose levels and fractionation schedules accepted, as per site standard concurrent chemotherapy is accepted patients with oligometastatic disease are allowed, where metastasis have been ablated with surgery or radiotherapy receiving (chemo)-radiotherapy to the thoracic disease with curative intent adults over 18, that have given oral and written informed consent before patient registration. Exclusion Criteria: concurrent immunotherapy previous radiotherapy to the thorax other uncontrolled malignancies; any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Katherina Farr, MD PhD
Phone
+4550303580
Email
katherina@oncology.au.dk
Facility Information:
Facility Name
Sydney West Radiation Oncology Network Westmead and Blacktown Hospitals
City
Sydney
State/Province
New South Wales
ZIP/Postal Code
2145
Country
Australia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eric Hau, MBBS PhD
Phone
0432207880
Email
Eric.Hau@health.nsw.gov.au
First Name & Middle Initial & Last Name & Degree
Eric Hau, MBBS PhD
Facility Name
Department of Oncology, Aarhus University Hospital
City
Aarhus
ZIP/Postal Code
DK-8000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Azza Khalil, MD, PhD
Phone
004578465000
Email
azza.khalil@auh.rm.dk
First Name & Middle Initial & Last Name & Degree
Line Sparvath
Phone
004578465000
Email
linspa@rm.dk
First Name & Middle Initial & Last Name & Degree
Katherina Farr, MD, PhD
First Name & Middle Initial & Last Name & Degree
Azza Khalil, MD, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
34418994
Citation
Khalil AA, Hau E, Gebski V, Grau C, Gee H, Nyeng TB, West K, Kramer S, Farlow D, Knap M, Moller DS, Hoffmann L, Farr KP. Personal innovative approach in radiation therapy of lung cancer- functional lung avoidance SPECT-guided (ASPECT) radiation therapy: a study protocol for phase II randomised double-blind clinical trial. BMC Cancer. 2021 Aug 21;21(1):940. doi: 10.1186/s12885-021-08663-1.
Results Reference
derived

Learn more about this trial

Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer

We'll reach out to this number within 24 hrs